Comparison of biological properties of [177 Lu]Lu-ProBOMB1 and [177 Lu]Lu-NeoBOMB1 for GRPR-targeting.
The gastrin-releasing peptide receptor (GRPR) is overexpressed in prostate cancer and other solid malignancies. Following up on our work on [68Ga]Ga-ProBOMB1 that had better imaging characteristics than [68Ga]Ga-NeoBOMB1, we investigated the effects of substituting 68Ga for 177Lu to determine if the resulting radiopharmaceuticals could be used with a therapeutic aim. We radiolabeled the bombesin antagonist ProBOMB1 (DOTA-pABzA-DIG-D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-ψ-Pro-NH2) with lutetium-177 and compared it with [177Lu]Lu-NeoBOMB1 (obtained in 54.2 ± 16.5 % isolated radiochemical yield with > 96% radiochemical purity and 440.8 ± 165.1 GBq/μmol molar activity) for GRPR targeting. Lu-NeoBOMB1 had better binding affinity for GRPR than Lu-ProBOMB1(Ki values: 2.26 ± 0.24 and 30.2 ± 3.23 nM). [177Lu]Lu-ProBOMB1 was obtained in 53.7 ± 5.4% decay-corrected radiochemical yield with 444.2 ± 193.2 GBq/μmol molar activity, and > 95% radiochemical purity. In PC-3 prostate cancer xenograft mice, tumor uptake of [177Lu]Lu-ProBOMB1 was 3.38 ± 1.00, 1.32 ± 0.24, and 0.31 ± 0.04 %ID/g at 1, 4 and 24 h p.i. However, the uptake in tumor was lower than [177Lu]Lu-NeoBOMB1 at all time points. [177Lu]Lu-ProBOMB1 was inferior to [177Lu]Lu-NeoBOMB1, which had better therapeutic index for the organs receiving the highest doses.